{ "schemaVersion": "deck-intelligence.v1", "id": "019de515-df71-7068-a98d-cc2a99c8892d", "slug": "c88233ba648814c9f5b65afc1926df6d", "title": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides", "subtitle": "Invivyd · 2023-06", "author": "Invivyd", "date": "2023-06-01 00:00:00", "pageCount": 11, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de515-df71-7068-a98d-cc2a99c8892d", "slug": "c88233ba648814c9f5b65afc1926df6d", "title": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides", "rawTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides", "authorId": "adagio-therapeutics", "authorName": "Invivyd", "authorDisplay": "Invivyd", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-06__adagio-therapeutics__investor-conf__c88233ba.pdf", "sourceUrl": "https://www.slidebook.io/company/adagio-therapeutics/presentation/c88233ba648814c9f5b65afc1926df6d/", "sourceDate": "2023-06-09 00:00:00", "presentationDate": "2023-06-01 00:00:00", "ingestedAt": "2026-05-01 19:48:29.257155+00", "status": "ready", "pageCount": 11, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": null, "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-06__adagio-therapeutics__investor-conf__c88233ba", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Conference Presentation Deck", "deck_type_slug": "investor-conference", "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 11, "pagesIndexed": 11, "pagesWithImages": 11, "pagesWithMetadata": 11, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 59, "chartCount": 4, "metricSlides": 0, "toolMatches": 4, "documentToolMatches": 0, "frameworkMatches": 0, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "evidence": "The deck follows a problem-agitate-solution narrative, starting with an urgent need, detailing the complications, and proposing a solution.", "isPrimary": true, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:08:30.283924+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 3, "name": "Problem", "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Agitate", "beatId": "9267716b-6700-4ffc-8701-d4f03cee81cc", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 10, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Solution", "beatId": "c71d1650-7012-4826-8d41-2bb5b4993bcd", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 6, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "4ce340fa-5923-4426-abff-c930e25c323b", "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.", "position": 0, "objective": "What is the cost of not addressing the urgent need for new therapeutics?", "confidence": 0.8, "extraction": { "at": "2026-07-16 23:08:30.426956+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 10, "from": 7, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9", "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.", "position": 1, "objective": "How can Invivyd's VYD222 address the unmet need?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:08:30.462896+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3cd1b85c-0360-4ca0-9b51-4fef7909380b", "evidence": "Jefferies Healthcare Conference, June 9, 2023", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 04:00:01.159194+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "b2a59d92-5cf5-44d4-82e5-e223d5f0f903", "evidence": "quote/pull-quote: Now, many people who are not well-protected by vaccines are in a dangerous and isolating situation—especially because the arsenal of effective COVID-19 treatments is shrinking for everyone as the virus", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 01:46:12.307383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "4ff66768-f70c-4753-a4e4-f32737541748", "evidence": "paragraph/paragraph: 8-18M people in the U.S.1-3 14M people in the E.U.4 are estimated to be immunocompromised due to a medical condition or immunosuppressive medication or treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 01:46:12.393001+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "a9a59549-097d-4719-b2ee-d3c35804704a", "evidence": "The slide presents a problem statement with data and statistics, highlighting the waning vaccine effectiveness against COVID-19 variants.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 01:46:02.573723+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/7yJsr-Xm8oEsrTfzZbWpU_NCZgxQix2DmpovCw7ygMQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jODgyMzNiYTY0ODgxNGM5ZjViNjVhZmMxOTI2ZGY2ZC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 212, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:15.302+00", "seconds": 3.246, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/1", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-1", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.046, "w": 0.146, "x": 0.764, "y": 0.083 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:15.302+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b44f7d98-a811-491d-ab59-7be9d8a4bc33", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.22, "x": 0.05, "y": 0.54 }, "kind": "paragraph", "text": "June 9, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:15.302+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49d67bc5-46b3-4f5e-b7ae-07661b480b5b", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.899, "x": 0.05, "y": 0.933 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:15.302+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fefd68b3-426e-411b-8063-41aa6977b73b", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.709, "x": 0.05, "y": 0.446 }, "kind": "title", "text": "Jefferies Healthcare Conference", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:15.302+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c84267d-70ec-4708-b069-2a731fa68f78", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "3cd1b85c-0360-4ca0-9b51-4fef7909380b", "evidence": "Jefferies Healthcare Conference, June 9, 2023", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 04:00:01.159194+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/MdQDLUCzSbn7OFXTqIYDTtHKESlOuykfNtgdWfsn6Zs/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jODgyMzNiYTY0ODgxNGM5ZjViNjVhZmMxOTI2ZGY2ZC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/UHf5Ed5WBJVemxy8GHwTkkRE9Nz4o9zR1LRG0DWjDbs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jODgyMzNiYTY0ODgxNGM5ZjViNjVhZmMxOTI2ZGY2ZC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/-BrsMzCIR1Am1kPvRiAnK9RWQdBY522SG6h5n_0N5cg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jODgyMzNiYTY0ODgxNGM5ZjViNjVhZmMxOTI2ZGY2ZC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "front_matter", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 3, "textChars": 6326, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:34:03.434+00", "seconds": 51.377, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/2", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-2", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.93, "x": 0.034, "y": 0.21 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"seek,\" \"could,\" \"intend,\" \"target,\" \"aim,\" \"project,\" \"designed to,\" \"estimate,\" \"believe,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, our belief that our existing cash resources will be sufficient to fund our operations into the second half of 2024; the future of the COVID-19 landscape including the expectation of continued evolution and emergence of new variants and subvariants; our ongoing research and clinical development plans, including with respect to VYD222; the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including the clinical trial design, objectives and anticipated data readouts from our VYD222 program; our expectation that our platform will rapidly and perpetually deliver a stream of monoclonal antibodies to keep pace with viral evolution and protect vulnerable populations from COVID-19; our expectation to engage in continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat; our expectations regarding the size of target patient populations and the potential market opportunity for our product candidates, as well as our market positioning; our expectations regarding the clinical utility and market acceptance of anti-SARS-CoV-2 monoclonal antibodies (\"mAbs\") and our product candidates; our belief that a mAb therapeutic that offers more robust protection against current SARS-CoV-2 variants would be an important addition to the COVID-19 medicine cabinet, especially for vulnerable populations; our expectations regarding the scope of any approved indication for our product candidates; our ability to successfully commercialize our product candidates; our belief that serum virus neutralizing titers are predictive of protection against symptomatic COVID-19 and have potential to be used as surrogates of clinical efficacy in future trials, potentially accelerating the clinical development path; the potential for an emergency use authorization (\"EUA\") or other regulatory approval of any of our product candidates; our plans to generate a robust pipeline of product candidates which, if authorized or approved, could be used in prevention or treatment of serious viral threats, starting with COVID-19 and expanding into influenza and other high-need indications; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: our ability to gain alignment with the applicable regulatory authorities on the clinical trial design and development pathway for VYD222 and the timing thereof; the timing and progress of our discovery, preclinical and clinical development activities; our ability to generate and utilize tools to discover and develop a pipeline of antibodies to treat current and potential future SARS-CoV-2 variants; the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in pre-clinical studies; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our clinical trials and platform-based approach to development; whether we are able to successfully monitor, analyze, engineer and optimize new product candidates and create a stream of monoclonal antibodies to keep pace with viral evolution; whether VYD222 or any other product candidate or combination of candidates is able to demonstrate and sustain neutralizing activity against predominant SARS-CoV-2 variant(s); whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; whether our research and development efforts will identify and result in safe and effective therapeutic options for infectious diseases other than COVID-19; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading \"Risk Factors\" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the \"SEC\"), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:34:03.434+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76690dcf-a611-4d59-8af8-5ef6905c7368", "parentComponentId": null }, { "bbox": { "h": 0.046, "w": 0.504, "x": 0.034, "y": 0.876 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc.\nAll trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:34:03.434+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68d00fdc-2c8b-4ecc-8285-57e8b07c9289", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.807, "x": 0.045, "y": 0.132 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:34:03.434+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3606f971-e167-4046-afe5-db67c7174728", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 740, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:17.059+00", "seconds": 4.22, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/3", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-3", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.642, "w": 0.43, "x": 0.047, "y": 0.255 }, "kind": "image", "text": "TIME Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19 Immunocompromised worry they're getting left behind again", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:17.059+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d4cee7f-51b0-43ea-8077-37df9c4c282e", "parentComponentId": null }, { "bbox": { "h": 0.229, "w": 0.429, "x": 0.52, "y": 0.29 }, "kind": "quote", "text": "Now, many people who are not well-protected by vaccines are in a dangerous and isolating situation—especially because the arsenal of effective COVID-19 treatments is shrinking for everyone as the virus evolves.¹", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:17.059+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59c11dc6-57fb-4019-9297-94445f6fe17e", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.429, "x": 0.52, "y": 0.647 }, "kind": "quote", "text": "The withdrawal of Evusheld is a disaster for our immunocompromised patients and illustrates the hard fight ahead against this virus.²", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:17.059+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b16801d2-eda3-4fd0-8eb2-cea530d60b0e", "parentComponentId": null }, { "bbox": { "h": 0.017, "w": 0.67, "x": 0.045, "y": 0.95 }, "kind": "source-note", "text": "Sources: 1. https://time.com/6251474/immunocompromised-covid-19-evusheld-fda/; 2. https://www.axios.com/2023/02/07/immunocompromised-covid-risk-left-behind-again", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:17.059+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1cd74db-beaf-40a7-aa44-b20039b82a1b", "parentComponentId": null }, { "bbox": { "h": 0.099, "w": 0.899, "x": 0.045, "y": 0.077 }, "kind": "title", "text": "THERE IS AN URGENT NEED FOR NEW THERAPEUTICS THAT PROTECT IMMUNOCOMPROMISED PEOPLE FROM COVID-19", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:17.059+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ac52c4e-7dd0-4baa-99eb-a5b32383d040", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "b2a59d92-5cf5-44d4-82e5-e223d5f0f903", "evidence": "quote/pull-quote: Now, many people who are not well-protected by vaccines are in a dangerous and isolating situation—especially because the arsenal of effective COVID-19 treatments is shrinking for everyone as the virus", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 01:46:12.307383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 6, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "4ce340fa-5923-4426-abff-c930e25c323b", "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.", "position": 0, "objective": "What is the cost of not addressing the urgent need for new therapeutics?", "confidence": 0.8, "extraction": { "at": "2026-07-16 23:08:30.426956+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 10, "textChars": 944, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:20.144+00", "seconds": 7.255, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/4", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-4", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.07, "x": 0.6, "y": 0.74 }, "kind": "list", "text": "Myeloma patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1659be59-be8b-4d7d-867a-4a50bd29ae3a", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.08, "x": 0.82, "y": 0.83 }, "kind": "list", "text": "People with uncontrolled HIV", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd128bdf-1376-49b3-903d-9133a5ac3378", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.08, "x": 0.82, "y": 0.39 }, "kind": "list", "text": "Organ transplant recipients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb818b21-e34c-4ce7-a7e7-d3ea49c0516b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.16, "x": 0.03, "y": 0.65 }, "kind": "list", "text": "People on immuno-suppressive drugs (e.g., MS, RA, IBD)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da45d2fc-7899-4f53-945d-1fb76bda9bf3", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.09, "x": 0.44, "y": 0.51 }, "kind": "list", "text": "Bone marrow transplant recipients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e489d123-78e9-4e6e-9c1f-7e8940e32cde", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.09, "x": 0.24, "y": 0.74 }, "kind": "list", "text": "Leukemia patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1b635ef-15e1-4421-82f9-f07ec0756acc", "parentComponentId": null }, { "bbox": { "h": 0.01, "w": 0.52, "x": 0.04, "y": 0.89 }, "kind": "paragraph", "text": "Examples of populations that may not mount an adequate immune response to COVID-19 vaccination5", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81ebe978-47ac-4ab3-871d-6b88ee77ff41", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.33, "x": 0.073, "y": 0.26 }, "kind": "paragraph", "text": "8-18M people in the U.S.1-3\n14M people in the E.U.4\nare estimated to be immunocompromised due to a\nmedical condition or immunosuppressive medication or\ntreatment", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bcd70bc9-e748-4d15-b35c-bce1cb96a257", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.96, "x": 0.03, "y": 0.95 }, "kind": "source-note", "text": "Sources: 1. Harpaz JAMA 2016; 2. Patel Emerg Infect Dis 2020; 3. U.S. Census Bureau Data; 4. European Cancer Patient Coalition: https://ecpc.org/joint-statement-on-the-protection-of-immunocompromised-patients/; 5. Lee BMJ 2022; https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html; MS, multiple sclerosis; RA, rheumatoid arthritis; IBD: inflammatory bowel disease", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c23a786-6162-41e7-abce-ed341bb2f1b2", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.889, "x": 0.046, "y": 0.08 }, "kind": "title", "text": "MILLIONS OF IMMUNOCOMPROMISED PEOPLE ARE IN URGENT NEED OF NEW THERAPEUTICS THAT PROVIDE PASSIVE IMMUNITY TO COVID-19", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.144+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1bddf89c-3dc3-4521-926b-fea3732efb01", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "4ff66768-f70c-4753-a4e4-f32737541748", "evidence": "paragraph/paragraph: 8-18M people in the U.S.1-3 14M people in the E.U.4 are estimated to be immunocompromised due to a medical condition or immunosuppressive medication or treatment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 01:46:12.393001+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 6, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "4ce340fa-5923-4426-abff-c930e25c323b", "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.", "position": 0, "objective": "What is the cost of not addressing the urgent need for new therapeutics?", "confidence": 0.8, "extraction": { "at": "2026-07-16 23:08:30.426956+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 79, "componentCount": 6, "textChars": 951, "nDataPoints": 9, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:19.713+00", "seconds": 6.047, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/5", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-5", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.45, "x": 0.53, "y": 0.32 }, "kind": "chart", "text": "Vaccine effectiveness against COVID-19-associated hospitalizations after bivalent booster compared with no vaccination²", "attrs": { "data_points": [ { "x": "7-59 days post bivalent booster", "y": 62, "series": "Immunocompetent" }, { "x": "7-59 days post bivalent booster", "y": 28, "series": "Immunocompromised" }, { "x": "120-179 days post bivalent booster", "y": 24, "series": "Immunocompetent" }, { "x": "120-179 days post bivalent booster", "y": 13, "series": "Immunocompromised" } ], "series_names": [ "Immunocompetent", "Immunocompromised" ], "x_axis_label": "Time post bivalent booster", "y_axis_label": "Vaccine effectiveness (%)" }, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40727c80-c066-4e6e-800a-6d517c31b624", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.45, "x": 0.045, "y": 0.32 }, "kind": "chart", "text": "Seroconversion rates (detectable Abs) in immunocompromised people vs. immunocompetent controls after two COVID-19 vaccine doses¹ [pre-Omicron]", "attrs": { "data_points": [ { "x": "Haematological cancers", "y": 98, "series": "Immunocompetent" }, { "x": "Haematological cancers", "y": 62, "series": "Immunocompromised" }, { "x": "Organ Transplant", "y": 98, "series": "Immunocompetent" }, { "x": "Organ Transplant", "y": 43, "series": "Immunocompromised" }, { "x": "Immune-Mediated Inflammatory Disorders", "y": 98, "series": "Immunocompetent" }, { "x": "Immune-Mediated Inflammatory Disorders", "y": 74, "series": "Immunocompromised" } ], "series_names": [ "Immunocompetent", "Immunocompromised" ], "x_axis_label": "Condition", "y_axis_label": "Seroconversion rates (%)" }, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a53ffd0e-b021-4282-8fe9-c60c76b5e4a9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.045, "y": 0.23 }, "kind": "paragraph", "text": "Immunocompromised people are less likely to have detectable SARS-CoV-2 antibodies following vaccination than immunocompetent people", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "815aaed6-4af0-4cc2-acb8-9eb6e330cae1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.53, "y": 0.23 }, "kind": "paragraph", "text": "Immunocompromised people generate less protection against severe outcomes than immunocompetent people after bivalent boosters", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fef252bc-4446-4b40-a06c-d1f002e92a6e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.91, "x": 0.045, "y": 0.94 }, "kind": "source-note", "text": "Source: 1. Lee BMJ 2022; 2. Centers for Disease Control and Prevention, Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023; Abs, antibodies", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d56a4023-de8c-479e-b352-62713fdb3064", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.915, "x": 0.045, "y": 0.08 }, "kind": "title", "text": "MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED RESPONSE TO VACCINES AND HAVE LESS PROTECTION AGAINST SEVERE COVID-19 OUTCOMES", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.713+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5fe6a10-5ee7-486d-8897-4f2b86c6468a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Agitate", "beatId": "9267716b-6700-4ffc-8701-d4f03cee81cc", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 6, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "4ce340fa-5923-4426-abff-c930e25c323b", "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.", "position": 0, "objective": "What is the cost of not addressing the urgent need for new therapeutics?", "confidence": 0.8, "extraction": { "at": "2026-07-16 23:08:30.426956+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 7, "textChars": 1093, "nDataPoints": 12, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:20.264+00", "seconds": 5.802, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/6", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-6", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.82, "x": 0.09, "y": 0.79 }, "kind": "paragraph", "text": "A monoclonal antibody (mAb) therapeutic that offers more robust protection against current variants would be an important addition to the COVID-19 medicine cabinet, especially for vulnerable populations", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "064ea0fd-e35e-4ba6-b572-fe8c5ce99fd6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.38, "x": 0.59, "y": 0.305 }, "kind": "paragraph", "text": "4-29% VE against infection with more recent Omicron variants up to 26 weeks from mRNA bivalent booster", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0bc17f21-0224-4e34-bc87-e139f1a7d480", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.48, "x": 0.035, "y": 0.305 }, "kind": "paragraph", "text": "45.7% VE against symptomatic Omicron B.1.1.529 at ≥10 wks after two doses of the BNT162b2 vaccine followed by a BNT162b2 booster", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29bce2ca-e657-49a8-b033-ae3b9257c880", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.47, "x": 0.015, "y": 0.97 }, "kind": "source-note", "text": "Sources: 1. Andrews N Engl J Med 2022; 2. Shrestha Open Forum Infectious Diseases 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5016a1f4-891f-4232-934f-e13eb1577d38", "parentComponentId": null }, { "bbox": { "h": 0.26, "w": 0.51, "x": 0.035, "y": 0.38 }, "kind": "table", "text": "VE against symptomatic COVID-19 in primarily immunocompetent¹\nMonovalent (BNT162b2)\n2-4 wks after 2nd dose\n≥25 wks after 2nd dose\n2-4 wks after booster\n≥10 wks after booster\nDelta B.1.617.2\n90.9%\n62.7%\n95.1%\n89.9%\nOmicron B.1.1.529\n65.5%\n8.8%\n67.2%\n45.7%", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a833c86-23b8-41fe-b8cd-d2f9468f519c", "parentComponentId": null }, { "bbox": { "h": 0.26, "w": 0.38, "x": 0.59, "y": 0.38 }, "kind": "table", "text": "VE against SARS-CoV-2 infection in primarily immunocompetent2\nBivalent Booster\nUp to 26 wks from bivalent booster\nOmicron BA.4/5 dominant phase\n29%\nOmicron BQ dominant phase\n20%\nOmicron XBB dominant phase\n4%", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9485e9a4-a0d4-4d41-a387-67b7a9247a7d", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.91, "x": 0.045, "y": 0.08 }, "kind": "title", "text": "EVEN IN PRIMARILY IMMUNOCOMPETENT POPULATIONS, VACCINE EFFECTIVENESS (VE) HAS WANED IN THE FACE OF VIRAL EVOLUTION", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.264+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8315bc9-af87-4df6-b8a3-549a16f11ff8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "a9a59549-097d-4719-b2ee-d3c35804704a", "evidence": "The slide presents a problem statement with data and statistics, highlighting the waning vaccine effectiveness against COVID-19 variants.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 01:46:02.573723+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 3, "name": "Problem", "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.9 }, { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 5, "name": "Agitate", "beatId": "9267716b-6700-4ffc-8701-d4f03cee81cc", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 6, "from": 3, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "4ce340fa-5923-4426-abff-c930e25c323b", "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.", "position": 0, "objective": "What is the cost of not addressing the urgent need for new therapeutics?", "confidence": 0.8, "extraction": { "at": "2026-07-16 23:08:30.426956+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "resolution", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 399, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:19.603+00", "seconds": 4.925, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/7", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-7", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.54, "w": 0.602, "x": 0.176, "y": 0.349 }, "kind": "chart", "text": "TOTAL REVENUE (MILLIONS)\n$1,400\n$1,270M\n$1,200\n$1,000\n$800\n$600\n$400\n$200\n$0\nH2 2021\nH1 2022\nH2 2022\n841% growth\n$914M\n$135M", "attrs": { "x_axis_label": "Period", "y_axis_label": "TOTAL REVENUE (MILLIONS)" }, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.603+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d05c51bf-c4c3-432f-bd96-5b498a347a02", "parentComponentId": null }, { "bbox": { "h": 0.014, "w": 0.296, "x": 0.034, "y": 0.954 }, "kind": "source-note", "text": "Sources: Results publicly reported by AstraZeneca.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.603+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ed617c5-e696-4a54-bcb3-3094d43b92c0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.653, "x": 0.176, "y": 0.24 }, "kind": "title", "text": "$2.2B in total revenue of Evusheld® in 2022, a mAb previously authorized to protect vulnerable populations from COVID-19", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.603+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "833943f5-9f52-4a0b-b1e0-2881e92d3f8a", "parentComponentId": null }, { "bbox": { "h": 0.089, "w": 0.899, "x": 0.046, "y": 0.079 }, "kind": "title", "text": "WE BELIEVE PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS IS A LONG-TERM, POTENTIALLY LARGE OPPORTUNITY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.603+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "246a347d-d04c-4ff8-8745-ae7ad2ccc578", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 10, "from": 7, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9", "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.", "position": 1, "objective": "How can Invivyd's VYD222 address the unmet need?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:08:30.462896+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 812, "nDataPoints": 5, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:20.637+00", "seconds": 5.766, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/8", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-8", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.41, "w": 0.939, "x": 0.031, "y": 0.201 }, "kind": "diagram", "text": "Healthy Adult Volunteers (N=30)\n8:2 Randomization (VYD222:Placebo)\nVYD222 Dose A (n=8)\nVYD222 Dose B (n=8)\nVYD222 Dose C (n=8)\nPlacebo (n=6)\nDay 1 (Dosing)\nEarly Safety, Tolerability, PK & sVNA Data\nMonth 12 (Last visit)\nLong Term Follow Up Data", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cdad6b79-8057-410e-8016-f8593d171bbe", "parentComponentId": null }, { "bbox": { "h": 0.16, "w": 0.44, "x": 0.518, "y": 0.726 }, "kind": "list", "text": "Dose-ranging trial will evaluate three different doses, each administered as a single IV push. All doses are designed to provide durability in the face of viral evolution and flexibility at the time of regulatory submission.\nTrial is designed to potentially enable rapid advancement into a pivotal Phase 3 trial.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a447b2cc-5163-47d8-9e12-fa7dc757bad0", "parentComponentId": null }, { "bbox": { "h": 0.16, "w": 0.44, "x": 0.044, "y": 0.726 }, "kind": "list", "text": "Primary: Safety and tolerability through 12 months\nSecondary: Pharmacokinetic (PK) and immunogenicity assessments\nExploratory: Serum virus neutralizing activity (sVNA)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4e08fcd-b9a6-4104-ba04-f774d83fbdc2", "parentComponentId": null }, { "bbox": { "h": 0.013, "w": 0.36, "x": 0.044, "y": 0.954 }, "kind": "source-note", "text": "Source: Clinicaltrials.gov (NCT05791318); IV, intravenous", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43b3da84-d755-48d6-a6ea-8bba46441478", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.16, "x": 0.044, "y": 0.68 }, "kind": "title", "text": "OBJECTIVES:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "685f5c75-81ed-4541-a8fa-436240e6dc76", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.302, "x": 0.518, "y": 0.68 }, "kind": "title", "text": "KEY DESIGN ELEMENTS:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.637+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e51cb6eb-63e8-4eaf-9f97-158a7ad67ad2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 10, "from": 7, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9", "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.", "position": 1, "objective": "How can Invivyd's VYD222 address the unmet need?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:08:30.462896+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 6, "textChars": 1241, "nDataPoints": 20, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:20.15+00", "seconds": 5.25, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/9", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-9", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.31, "w": 0.23, "x": 0.25, "y": 0.37 }, "kind": "chart", "text": "Reported protection against symptomatic COVID-19 (%) (Data from Phase 2/3 trials and real-world vaccine effectiveness studies) Geometric mean serum neutralizing titer (FRNT50)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Scatter plot", "slug": "scatter", "status": "active", "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2", "version": 1, "description": null }, "framework": null }, "subkind": "scatter", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12397262-59e9-4e84-9e29-7757d27925b0", "parentComponentId": null }, { "bbox": { "h": 0.46, "w": 0.19, "x": 0.489, "y": 0.33 }, "kind": "list", "text": "AZD1222/WT (2nd dose + 14-28d)\nAZD1222/Alpha (2nd dose + 14-28d)\nAZD1222/Gamma (2nd dose + 14-28d)\nAZD1222/Delta (2nd dose + 14-28d)\nAZD1222/Omicron (2nd dose + 28d)\nBNT162b2/WT (2nd dose + 7-17d)\nBNT162b2/Alpha (2nd dose + 7-17d\nBNT162b2/Beta (2nd dose + 7-17d)\nBNT162b2/Gamma (2nd dose + 7-17d)\nBNT162b2/Delta (2nd dose + 7-17d)\nBNT162b2/Delta (2nd dose + 6M)\nBNT162b2/Delta (3rd dose + 28d)\nBNT162b2/Omi BA.1 (2nd dose + 6M)\nBNT162b2/WT (1st dose + 28d)\nadintrevimab/Omi BA.1/BA1.1 (d28)\nadintrevimab/Omi BA.1/BA1.1 (d60)\nadintrevimab/Omi BA.1/BA1.1 (d90)\nadintrevimab/Delta (d90)\nadintrevimab/Delta (d180)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d432ffc-d2a0-4979-b919-f5c73c9e5c46", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.59, "x": 0.18, "y": 0.869 }, "kind": "paragraph", "text": "Strong scientific rationale for using surrogates of clinical efficacy in future trials, potentially accelerating clinical development path", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ac82f11-eb34-4777-90eb-56971abae26b", "parentComponentId": null }, { "bbox": { "h": 0.013, "w": 0.46, "x": 0.02, "y": 0.973 }, "kind": "source-note", "text": "Source: Schmidt Sci Transl Med 2023; FRNT, focus reduction neutralization test", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d855116-62f1-412c-b5aa-86e0e6172a8f", "parentComponentId": null }, { "bbox": { "h": 0.053, "w": 0.605, "x": 0.17, "y": 0.227 }, "kind": "title", "text": "Serum neutralizing titers (either mAb or vaccine-induced) correlate with protection against symptomatic SARS-CoV-2 infection across multiple variants", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75d5cfd5-dba4-4d76-b035-efbc09d483cf", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.909, "x": 0.046, "y": 0.08 }, "kind": "title", "text": "SERUM VIRUS NEUTRALIZING ANTIBODY TITERS MAY PREDICT PROTECTION AGAINST SYMPTOMATIC COVID-19", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:20.15+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "228af1eb-8cac-4423-a4df-71d561ba30d6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 9, "name": "Solution", "beatId": "c71d1650-7012-4826-8d41-2bb5b4993bcd", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 7, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9", "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.", "position": 1, "objective": "How can Invivyd's VYD222 address the unmet need?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:08:30.462896+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "function": "propose_solution", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "propose_solution", "functionCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-185b-74e9-bdfd-ea8cf318563f", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 507, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:19.395+00", "seconds": 4.162, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/10", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-10", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.076, "w": 0.847, "x": 0.082, "y": 0.293 }, "kind": "paragraph", "text": "Providing vulnerable populations, such as immunocompromised people, with protection from COVID-19 is a long-term, large opportunity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.395+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a6e5368-5481-4c70-b070-8d68670147b6", "parentComponentId": null }, { "bbox": { "h": 0.076, "w": 0.847, "x": 0.082, "y": 0.733 }, "kind": "paragraph", "text": "Well capitalized with $333.4 million in cash, cash equivalents and marketable securities as of March 31, 2023 expected to support operating runway into second half of 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.395+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62fd68ff-fb8b-4306-9847-b68cc16a4e48", "parentComponentId": null }, { "bbox": { "h": 0.076, "w": 0.847, "x": 0.082, "y": 0.513 }, "kind": "paragraph", "text": "Initial data readout from Phase 1 VYD222 clinical trial planned for Q2 2023, including early insights into serum virus neutralizing activity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.395+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a964b7a1-bbb6-4de1-a332-0bf5e1319768", "parentComponentId": null }, { "bbox": { "h": 0.016, "w": 0.018, "x": 0.959, "y": 0.969 }, "kind": "source-note", "text": "10", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.395+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b92be178-3144-4e76-9303-dd80bb9740a0", "parentComponentId": null }, { "bbox": { "h": 0.099, "w": 0.879, "x": 0.043, "y": 0.07 }, "kind": "title", "text": "INVIVYD IS POSITIONED TO POTENTIALLY FULFILL A LARGE UNMET NEED", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:19.395+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef24cf69-e8a1-44bc-8dbc-4b00e9d8a107", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 9, "name": "Solution", "beatId": "c71d1650-7012-4826-8d41-2bb5b4993bcd", "matchId": "1abc1cb7-e128-4ba3-a59d-52524511105e", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.9 } ], "loops": [ { "to": 10, "from": 7, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9", "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.", "position": 1, "objective": "How can Invivyd's VYD222 address the unmet need?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:08:30.462896+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "appendix", "function": "other", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 3, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 08:33:18.87+00", "seconds": 3.409, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/11", "deck": "/decks/019de515-df71-7068-a98d-cc2a99c8892d", "deckAnchor": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-11", "deckJson": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.179, "x": 0.765, "y": 0.07 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:18.87+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29c77811-980b-484f-bf18-cfdbd570dc71", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.726, "x": 0.138, "y": 0.93 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:18.87+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2c377e5-2cc8-4b8a-9e3b-417a27117fc0", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.29, "x": 0.048, "y": 0.437 }, "kind": "title", "text": "Thank You", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 08:33:18.87+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51e316df-3c22-4775-aa12-415cb7199017", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 3, "to": 6, "label": "Problem", "description": "Slides 3-6 detail the urgent need and complications for immunocompromised people." }, { "from": 5, "to": 6, "label": "Agitate", "description": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness." }, { "from": 9, "to": 10, "label": "Solution", "description": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need." } ], "loops": [ { "from": 3, "to": 6, "label": "Cost Of Inaction", "description": "What is the cost of not addressing the urgent need for new therapeutics?" }, { "from": 7, "to": 10, "label": "Jobs To Be Done", "description": "How can Invivyd's VYD222 address the unmet need?" } ] }